IRCT20210730052022N1 IRCT 2021-11-15 Shiraz University of Medical Sciences The effect of Empagliflozin on Glucagon, Beta hydroxybutyrate and insulin levels in type 2 diabetic patients Assessment of serum levels of Beta hydroxybutyrate, Glucagon, Cortisol and Insulin before and after one month treatment with Empagliflozin in comparison with Metformin in type 2 diabetic patients 2021-09-23 anticipated 50 Complete https://irct.ir/trial/58003 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: Block randomisation In this study patients with type 2 diabetes who referred to our clinics will be randomized in to two groups according to block randomisation list with block size of 6. The control group will receive Metformin and the intervention group will receive Empagliflozin and Metformin. In this study the participants are unaware of the group assigned to them by the researcher, Blinding description: The main researcher will assign the patients to their groups based on the randomisation method which was considered for this study. The participants, the staff who collect data or assess the outc omes will be unaware of the allocated group of the patients. N/A Type 2 diabetes mellitus. Intervention 1: Intervention group: patients with type 2 diabetes who received Metformin for at least three months but their HbA1c is greater than 7 to 9%. They will receive 10 miligram tablets of Empagliflozin (produced by Abidi Pharmaceuticals company) daily in addition to Metformin for one month. Intervention 2: Control group: patients with type 2 diabetes who have taken Metformin for at least three months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is This study contains other sections that have not yet been completed.